Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126483) titled 'Induction chemoimmunotherapy followed by chemoradiotherapy and consolidation immunotherapy versus PACIFIC regimen for unresectable stage III NSCLC: a propensity-matched multicenter real-world study' on June 9.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Zhongshan Hospital, Fudan University
Condition:
Lung cancer
Intervention:
PACIFIC Group (At least one cycle of concurrent chemotherapy during radiotherapy
radiotherapy dose of at least 56 Gy
at least 4 cycles of durvalumab immunotherapy maintenance after completion of chemoradiotherapy.):None
Induction Chemoimmunotherapy-Chem...